Topblan Soft Weighted Blanket 15lbs excellence 48”x72” Adult Fuzzy Sherp,Home Kitchen , Bedding , Blankets Throws,Topblan,Adult,(15lbs,48”x72”),,Fuzzy,$34,/interdespise1655275.html,Weighted,Blanket,Sherp,Soft,Home Kitchen , Bedding , Blankets Throws,Topblan,Adult,(15lbs,48”x72”),,Fuzzy,$34,/interdespise1655275.html,Weighted,Blanket,Sherp,Soft $34 Topblan Soft Weighted Blanket (15lbs,48”x72”), Adult Fuzzy Sherp Home Kitchen Bedding Blankets Throws $34 Topblan Soft Weighted Blanket (15lbs,48”x72”), Adult Fuzzy Sherp Home Kitchen Bedding Blankets Throws Topblan Soft Weighted Blanket 15lbs excellence 48”x72” Adult Fuzzy Sherp

Topblan Soft Cheap super special price Weighted Blanket 15lbs excellence 48”x72” Adult Fuzzy Sherp

Topblan Soft Weighted Blanket (15lbs,48”x72”), Adult Fuzzy Sherp


Topblan Soft Weighted Blanket (15lbs,48”x72”), Adult Fuzzy Sherp


Product Description

weighted blanket fuzzyweighted blanket fuzzy

Topblan - All For A Good Night’s Sleep

Treat yourself with the most relaxing sleep with Topblan Sherpa weighted blankets! Topblan ribbed stripe fleece Sherpa heavy blanket is made of top-quality microfiber featuring soft fleece top and warm Sherpa bottom to offer the warmest snuggles. Non-toxic ceramic beads sewn in the very middle help relieve pressure, elevate comfort, lift up spirit, and help with deep sleep.

weighted blanket softweighted blanket soft

Warmest Snuggles Anytime Anywhere

weighted blanket topblanweighted blanket topblan
adult weighted blanketadult weighted blanket

Tips About Wash and Care

  • Spot clean or wash in a commercial washer on gentle cycle
  • Wash with cold water
  • Air dry or tumble dry on low heat
  • No ironing / bleaching

Topblan Soft Weighted Blanket (15lbs,48”x72”), Adult Fuzzy Sherp

November, 2021

No. 106 (11)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days

Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma

Transducin β-like protein 1 (TBL1) plays a crucial role in controlling the stability of regulatory proteins involved in cell proliferation and autophagy induction. This study revealed that, unlike normal B cells, diffuse large B-cell lymphoma cells express abundant levels of TBL1 and its overexpression correlates with poor clinical outcome. Targeting TBL1 promoted lymphoma cell death in vitro and in vivo. These results provide the rationale for targeting TBL1 as a novel therapeutic strategy in diffuse large B-cell lymphoma.

Youssef Youssef et al.


Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro

The authors of this study developed a single-chain antibody that targets a shear gradient-specific conformation of von Willebrnad factor (VWF). In vitro studies showed that this antibody specifically reduces VWF-GPIbα binding and thrombus formation at sites of shear rate gradients but does not block platelet deposition and aggregation under constant shear rate. This characteristic places the antibody in a new class of antiplatelet therapy for selective blockade of pathological thrombus formation while maintaining normal hemostasis.

Thomas Hoefer et al.

Case Report

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

A 26-year-old female developed vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis and bi-hemispheric hemorrhage following the first dose of the ChAdOx1 nCoV-19 vaccine. The treatment protocol, based on intravenous immunoglobulins, dexamethasone and argatroban was successful with almost complete clinical, laboratory and radiological response. This experience supports the application of an early and multidisciplinary therapeutic approach in cases of VITT, with the possibility of avoiding deaths and obtain a resolution of the syndrome.

Sara Bonato et al.


Allogeneic hematopoietic stem cell transplantation from non-sibling 10/10 HLA-matched related donors: a single-center experience

This retrospective study compared the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) in 23 patients with hematologic malignancies transplanted from non-sibling fully matched related donors to that of patients who underwent conventional haplo-HSCT. Subjects transplanted from fully matched related donors showed trends to a higher relapse rate and lower cumulative incidence of grade II-IV acute graft-versus-host disease, but overall survival was similar. The authors concluded that individualized adjustment of the immunosuppressive treatment is reasonable for this category of patients.

Yaoyao Shen et al.